MedTrace Logo

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

NCT03142204 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-05

No results posted yet for this study

Summary

This is a Phase 1 study is to visualize biodistribution of a PET tracer called \[18F\]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.

Conditions

Interventions

DRUG

[18F]F-AraG

Single dose IV injection of \[18F\]F-AraG for each imaging day.

Sponsors & Collaborators

  • UCSF Imaging Center at China Basin

    collaborator UNKNOWN

  • CellSight Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert R Flavell, M.D., Ph.D. · UCSF Department of Radiology & Biomedical Imaging

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2024-05-31
Completion
2024-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03142204 on ClinicalTrials.gov